Cellular Biomedicine Group
Cellular Biomedicine Group is a biotechnology company developing cell therapies for degenerative and cancerous diseases.
All edits
A clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases
Cellular Biomedicine Group, Inc, a wholly-owned subsidiary of CBMG Holdings, develops proprietary cell therapies for the treatment of cancer and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards.
Our technology includes 2 major cell platforms:
- Immune Cell therapy for treatment of a broad range of cancers using Cancer Vaccines, Chimeric Antigen Receptor T cell (“CAR-T”), TCR-T and TIL Technologies
- Human adipose-derived mesenchymal progenitor cells (“haMPC”) for treatment of joint and autoimmune diseases
Our primary research and manufacturing facilities are located in China. Our cellular platforms are based on technologies developed both in-house and obtained through acquisition, licensing and collaboration arrangements with other companies.
Cellular Biomedicine Group brings together the world’s latest technology with industry-leading scientists and professors to research and develop safe treatments for those with serious conditions and diseases.
We are proud to have a share in an emerging field that has great potential for a significant positive impact on society. Our directors, scientists, doctors and employees share a sense of responsibility that ensures we maintain stringent international safety and quality control standards and focus on the patients and caregivers who will benefit the most from the application of breakthroughs in stem cell technology and immuno-oncology.
We are focused on developing and marketing safe and effective regenerative and cell-based therapies based on our cellular platforms, to treat cancers and degenerative diseases including including osteoarthritis and tissue damage. We have developed proprietary practical knowledge in the use of cell-based therapeutics that we believe could be used to help a great number of people suffering from cancer and serious chronic diseases.
Our technology includes 2 major cell platforms:
Stem Cell and Cancer Immune Cell
The unique lines of adult adipose-derived stem cells and the immune cell therapies enable us to create multiple cell formulations in treating specific medical conditions and diseases, as well as applying single cell types in a specific treatment protocol. Our facilities are certified to meet the international standards NSF/ANSI 49, ISO-14644 (or equivalent), ANSI/NCSL Z-540-1 and 10CFR21, as well as Chinese CFDA standards CNAS L0221. In addition to standard protocols, we use proprietary processes and procedures for manufacturing our cell lines, comprised of:
- Vertically-integrated CMC for CAR-T Cell Therapy
- Banking processes that ensure cell preservation and viability
- DNA identification for stem cell origin chain of custody
- Bio-safety testing at independently certified laboratories
A clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases
Cellular Biomedicine Group, Inc, a wholly-owned subsidiary of CBMG Holdings, develops proprietary cell therapies for the treatment of cancer and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards.
Our technology includes 2 major cell platforms:
- Immune Cell therapy for treatment of a broad range of cancers using Cancer Vaccines, Chimeric Antigen Receptor T cell (“CAR-T”), TCR-T and TIL Technologies
- Human adipose-derived mesenchymal progenitor cells (“haMPC”) for treatment of joint and autoimmune diseases
Our primary research and manufacturing facilities are located in China. Our cellular platforms are based on technologies developed both in-house and obtained through acquisition, licensing and collaboration arrangements with other companies.
Cellular Biomedicine Group brings together the world’s latest technology with industry-leading scientists and professors to research and develop safe treatments for those with serious conditions and diseases.
We are proud to have a share in an emerging field that has great potential for a significant positive impact on society. Our directors, scientists, doctors and employees share a sense of responsibility that ensures we maintain stringent international safety and quality control standards and focus on the patients and caregivers who will benefit the most from the application of breakthroughs in stem cell technology and immuno-oncology.
We are focused on developing and marketing safe and effective regenerative and cell-based therapies based on our cellular platforms, to treat cancers and degenerative diseases including including osteoarthritis and tissue damage. We have developed proprietary practical knowledge in the use of cell-based therapeutics that we believe could be used to help a great number of people suffering from cancer and serious chronic diseases.
Our technology includes 2 major cell platforms:
Stem Cell and Cancer Immune Cell
The unique lines of adult adipose-derived stem cells and the immune cell therapies enable us to create multiple cell formulations in treating specific medical conditions and diseases, as well as applying single cell types in a specific treatment protocol. Our facilities are certified to meet the international standards NSF/ANSI 49, ISO-14644 (or equivalent), ANSI/NCSL Z-540-1 and 10CFR21, as well as Chinese CFDA standards CNAS L0221. In addition to standard protocols, we use proprietary processes and procedures for manufacturing our cell lines, comprised of:
- Vertically-integrated CMC for CAR-T Cell Therapy
- Banking processes that ensure cell preservation and viability
- DNA identification for stem cell origin chain of custody
- Bio-safety testing at independently certified laboratories
Find more companies like Cellular Biomedicine Group
